E.g., 09/23/2023
E.g., 09/23/2023

2023

Other
27/07/2023
14:27
Update 2023 Annual Calendar of Corporate Events
Financial data
27/07/2023
13:18
Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed
Products
17/07/2023
07:03
DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease
Other
03/07/2023
11:48
Suspension of the effectiveness of the disqualiffying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa
Products
13/06/2023
15:18
DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark
Financial Disclosures
07/06/2023
14:40
Communication of total amount of voting rights (7 June 2023)
Other
05/06/2023
21:58
Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment.
Acquisition / Partnership
26/05/2023
07:10
DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM
Financial data
09/05/2023
11:56
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023
Other
28/04/2023
12:52
Shareholders' Meeting 2023
Financial Disclosures
27/03/2023
15:52
Update 2023 Annual Calendar of Corporate Events
Financial data
27/03/2023
14:38
Dividend coupon date correction
Financial data
27/03/2023
13:35
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE
Products
17/03/2023
22:05
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance
Acquisition / Partnership
28/02/2023
16:06
Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed
Acquisition / Partnership
13/02/2023
22:03
CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN
Financial Disclosures
07/02/2023
12:01
Update 2023 Annual Calendar of Corporate Events

2022

Other
01/12/2022
18:30
2023 Annual Calendar of Corporate Events
Products
09/11/2022
07:04
DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance
Products
07/11/2022
07:12
DiaSorin commercializes molecular reagent for monkeypox virus
Financial data
27/10/2022
13:44
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards
Products
05/10/2022
06:37
DiaSorin furthers its collaboration with BARDA for the LIAISON® NES
Products
14/09/2022
00:29
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE
Financial data
03/08/2022
12:26
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards
Products
14/07/2022
20:00
DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test
Other
07/06/2022
18:06
Execution of the project for the redefinition of the corporate structure of DiaSorin
Products
20/05/2022
07:08
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay
Acquisition / Partnership
09/05/2022
07:02
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™
Financial Disclosures
06/05/2022
17:33
Update 2022 Annual Calendar of Corporate Events
Financial data
06/05/2022
16:45
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards
Financial Disclosures
02/05/2022
12:55
Publication of the summary report of the votes cast
Other
29/04/2022
16:26
Shareholders' meeting 2022
Financial Disclosures
22/04/2022
12:37
New proposal for resolution related to the remuneration of the Board of Statutory Auditors
Financial Disclosures
13/04/2022
16:43
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative
Financial Disclosures
08/04/2022
19:13
Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution
Financial Disclosures
08/04/2022
09:53
Update annual calendar of corporate events 2022
Other
05/04/2022
09:51
Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999
Other
04/04/2022
18:12
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l.
Financial data
16/03/2022
17:39
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021
Products
08/03/2022
07:13
DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel
Products
13/01/2022
07:24
DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant

2021

Other
21/12/2021
11:07
2022 Annual Calendar of Corporate Events
Financial data
16/12/2021
22:47
DiaSorin 2022-2025 Strategic Plan
Products
30/11/2021
19:10
DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant
Products
29/11/2021
07:06
DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer
Products
23/11/2021
07:10
DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark
Financial data
11/11/2021
16:56
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021
Other
05/11/2021
11:22
Weekly report treasury shares buy-back
Other
02/11/2021
20:00
Conclusion treasury shares buy-back plan
Other
02/11/2021
19:57
Weekly report treasury shares buy-back
Other
27/10/2021
16:35
Issuance of the "Physical Settlement Notice"
Other
07/10/2021
11:45
Publication of the summary report of the votes
Other
04/10/2021
12:27
The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase
Products
18/09/2021
08:16
DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test
Other
30/07/2021
18:43
Start up of the treasury shares buy-back plan
Financial data
30/07/2021
12:57
DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex
Other
22/07/2021
18:28
Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999
Acquisition / Partnership
14/07/2021
15:05
DiaSorin announces completion of the Acquisition of Luminex Corporation
Acquisition / Partnership
09/07/2021
07:34
DiaSorin obtains all approvals necessary to complete the acquisition of Luminex
Acquisition / Partnership
21/06/2021
18:49
The Shareholders’ meeting of Luminex Corporation approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin
Products
15/06/2021
06:56
DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E
Other
07/06/2021
15:16
Communication on total amount of voting rights
Acquisition / Partnership
03/06/2021
07:47
DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ
Products
25/05/2021
07:03
DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection
Products
21/05/2021
07:02
DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2
Products
20/05/2021
08:27
DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market
Financial data
14/05/2021
16:10
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021
Financial data
28/04/2021
17:46
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028
Financial data
28/04/2021
07:54
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028
Other
22/04/2021
15:58
Shareholders' meeting April 22, 2021
Products
21/04/2021
07:02
DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology
Products
20/04/2021
18:58
DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark
Other
14/04/2021
10:05
Communication voting rights amount
Other
12/04/2021
11:08
Weekly report treasury shares buy-back
Acquisition / Partnership
11/04/2021
19:47
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
Other
06/04/2021
08:53
Start up buy-back plan
Acquisition / Partnership
06/04/2021
07:06
DiaSorin announces its strategic collaboration with Lumos Diagnostics
Products
30/03/2021
07:01
DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test
Products
29/03/2021
07:02
DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S.
Financial data
11/03/2021
16:37
Dividend coupon date correction
Financial data
11/03/2021
15:31
Revenues, Profitability and Cash Flow Generation hit record highs in 2020
Products
23/02/2021
06:11
DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market
Other
27/01/2021
18:50
2021 Annual Calendar of Corporate Events
Products
11/01/2021
18:43
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test

2020

Products
29/12/2020
18:22
DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance
Other
17/12/2020
17:57
DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics
Other
07/12/2020
10:35
Communication on total amount of voting rights
Other
04/12/2020
16:14
Form 3F (November 2020)
Products
01/12/2020
06:33
DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market
Financial data
11/11/2020
12:41
North America growth drives up revenues and profitability in the first 9 months of 2020
Products
26/10/2020
18:30
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients
Other
23/10/2020
19:41
Conclusion treasury shares buy-back plan
Other
23/10/2020
19:37
Weekly report treasury shares buy-back
Other
16/10/2020
18:28
Weekly report treasury shares buy-back
Products
01/10/2020
07:45
DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market
Products
01/10/2020
07:32
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market
Acquisition / Partnership
23/09/2020
07:16
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China
Other
16/09/2020
14:30
Update Annual Calendar of Corporate Events 2020
Products
16/09/2020
07:25
DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens
Acquisition / Partnership
08/09/2020
07:31
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
Products
07/09/2020
18:22
FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay
Products
06/08/2020
07:25
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone
Other
31/07/2020
16:04
Weekly report treasury shares buy-back
Financial data
30/07/2020
13:16
North America business growth drives Group revenues and profitability in H1 2020
Other
24/07/2020
17:19
Weekly report treasury shares buy-back
Other
17/07/2020
18:19
Weekly report treasury shares buy-back
Other
10/07/2020
18:23
Weekly report treasury shares buy-back
Products
09/07/2020
07:27
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study
Products
07/07/2020
07:22
DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay
Products
30/06/2020
07:25
DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients
Other
19/06/2020
17:20
Weekly report treasury shares buy-back
Other
17/06/2020
16:09
Start up of the treasury shares buy-back plan
Products
12/06/2020
07:30
DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay
Other
10/06/2020
15:40
Shareholders' Meeting June 10, 2020
Products
03/06/2020
14:16
The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA
02/06/2020
14:58
Communication total amount voting rights (record date)
Products
18/05/2020
11:28
The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada
Financial data
13/05/2020
13:15
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic
Products
25/04/2020
16:49
DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG
Products
17/04/2020
18:25
DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19
Products
07/04/2020
07:14
IgG test to detect immune response to SARS-CoV-2
Other
26/03/2020
18:14
Update Annual Calendar of Corporate Events 2020
Other
21/03/2020
20:29
Shareholders' Meeting date change
Products
20/03/2020
07:28
DiaSorin COVID-19 test has received FDA Emergency Use Authorization
Products
13/03/2020
17:16
DiaSorin received BARDA funding to develop a rapid COVID-19 test
Financial data
11/03/2020
13:43
DiaSorin - Cash flow generation and net profit hit record highs in 2019
Products
10/03/2020
08:20
DiaSorin - Development of Coronavirus test
Acquisition / Partnership
02/03/2020
08:04
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology
Other
07/02/2020
08:06
Communication on total amount of voting rights
Other
15/01/2020
16:51
Annual Calendar of Corporate Events 2020

2019

Products
16/12/2019
14:10
Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay
Other
06/12/2019
18:12
Press Release
Other
06/12/2019
18:11
Press Release
Other
06/12/2019
18:08
Communication on total amount of voting rights
Products
27/11/2019
07:59
DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET
Products
11/11/2019
09:46
DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET
Financial data
06/11/2019
13:00
Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019
Products
30/10/2019
09:55
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET
Products
22/10/2019
14:10
DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET
Other
07/10/2019
10:20
Communication on total amount of voting rights
Products
24/09/2019
10:10
DiaSorin launches VZV Direct molecular test in Europe
Financial data
31/07/2019
13:00
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability.
Financial data
10/06/2019
18:23
DiaSorin presents its 2019-2022 Industrial Plan
Acquisition / Partnership
05/06/2019
07:38
DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease
Products
29/05/2019
15:06
DiaSorin launches VZV DIRECT molecular test in the United States
Financial data
09/05/2019
13:14
DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019
Products
06/05/2019
15:19
DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL
Other
30/04/2019
12:28
Update Annual Calendar of Corporate Events 2019
Other
24/04/2019
17:24
DiaSorin: Shareholders' Meeting 2019
Other
12/04/2019
08:59
Communication on total amount of voting rights
Other
05/04/2019
09:33
Communication on total amount of voting rights
Other
03/04/2019
20:18
Lists publication
Products
03/04/2019
10:32
DiaSorin launches the anaemia panel on Liaison XL in Europe
Financial data
14/03/2019
14:16
Growth in revenues, profitability and net profit in 2018
Other
07/03/2019
11:45
Communication on total amount of voting rights
Other
06/03/2019
08:45
A new Group website for DiaSorin: www.diasoringroup.com
Other
07/02/2019
15:15
Communication on total amount of voting rights (February 7, 2019)
Products
31/01/2019
22:30
DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market
Products
03/01/2019
13:30
DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States

2018

Products
21/12/2018
11:30
DiaSorin launches 3 new primer pairs for use in molecular testing
Financial data
04/12/2018
08:00
DiaSorin's stocks listed in the FTSE MIB
Products
19/11/2018
15:00
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States
Financial data
07/11/2018
13:00
DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018
Products
17/10/2018
11:51
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market
Products
12/10/2018
11:47
DiaSorin launches Simplexa VZV Direct molecular assay in the european market
Acquisition / Partnership
09/10/2018
11:35
DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom
Products
17/09/2018
11:28
DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen
Financial data
07/08/2018
08:45
Communication on total amount of voting rights
Financial data
02/08/2018
12:45
The Board of Directors approves the results for the first half of 2018
Products
27/07/2018
12:00
DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform
Financial data
03/07/2018
18:30
Report treasury shares buy-back
Financial data
03/07/2018
18:30
Annex 3F (treasury shares buy back July 2018)
Financial data
03/07/2018
18:30
Conclusion treasury shares buy-back plan
Financial data
03/07/2018
18:30
Annex 3F (treasury shares buy back June 2018)
Financial data
29/06/2018
18:15
Weekly report treasury shares buy-back
Financial data
22/06/2018
20:30
Weekly report treasury shares buy-back
Financial data
15/06/2018
21:00
Weekly report treasury shares buy-back
Products
12/06/2018
14:15
DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia
Financial data
08/06/2018
23:15
Weekly report treasury shares buy-back
Financial data
04/06/2018
13:15
Annex 3F (treasury shares buy back May 2018)
Financial data
01/06/2018
20:15
Weekly report treasury shares buy-back
Financial data
25/05/2018
22:30
Weekly report treasury shares buy-back
Financial data
19/05/2018
01:45
Weekly report treasury shares buy-back
Financial data
11/05/2018
20:15
Weekly report treasury shares buy-back
Financial data
08/05/2018
14:30
The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018
Financial data
03/05/2018
20:15
Start up treasury shares buy-back plan
Financial data
24/04/2018
14:00
Annex 3F (treasury shares buy back)
Financial data
23/04/2018
18:30
Annual General Meeting 2018
Financial data
19/04/2018
21:15
Conclusion treasury shares buy-back plan
Financial data
19/04/2018
21:00
Weekly report treasury shares buy-back
Financial data
13/04/2018
20:30
Weekly report treasury shares buy-back
Financial data
06/04/2018
19:45
Weekly report treasury shares buy-back
Products
05/04/2018
12:00
DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis)
Financial data
04/04/2018
20:00
Start up treasury shares buy-back plan
Products
28/03/2018
18:45
DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test
Financial data
07/03/2018
15:30
DiaSorin: FY 2017 Results
Financial data
30/01/2018
11:45
DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime
Acquisition / Partnership
08/01/2018
09:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems
Acquisition / Partnership
08/01/2018
09:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems

2017

Products
12/12/2017
13:15
DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test
Other
29/11/2017
19:30
Resignation of a Strategic Executive of the Company
Financial data
09/11/2017
14:15
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED
Financial data
29/09/2017
15:00
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS
Acquisition / Partnership
29/09/2017
14:15
DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS
Products
21/09/2017
12:45
DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit
Financial data
03/08/2017
14:45
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017
Products
28/07/2017
14:45
DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS
Acquisition / Partnership
25/07/2017
21:00
DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS
Products
10/07/2017
13:30
DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP
Financial data
26/06/2017
09:45
DiaSorin presents its 2017-2019 Industrial Plan
Acquisition / Partnership
23/06/2017
09:30
DiaSorin and TECAN to collaborate in new platform development
Acquisition / Partnership
22/06/2017
19:45
DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays
Products
23/05/2017
11:45
DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders
Products
16/05/2017
13:00
DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality
Financial data
08/05/2017
19:30
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow
Financial data
27/04/2017
18:45
DiaSorin - Annual General Meeting 2016
Products
21/04/2017
18:45
DiaSorin receives authorization for the distribution of Zika IgM test in Europe
Products
06/04/2017
18:00
DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test
Financial data
08/03/2017
15:30
The Board of Directors approves the results for FY'16
Products
21/02/2017
11:30
DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market
Products
26/01/2017
12:45
DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE

2016

Financial data
19/12/2016
10:00
Co-optation of a Director
Financial data
10/11/2016
01:00
DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016
Products
02/11/2016
01:00
DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST
Acquisition / Partnership
30/08/2016
02:00
DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market
Products
22/08/2016
02:00
DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY
Financial data
04/08/2016
02:00
The Board of Directors approves results for H1'16
Products
28/07/2016
02:00
DiaSorin starts selling Vitamin D in Japan
Products
14/07/2016
02:00
DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia
Financial data
10/06/2016
02:00
Conclusion buy-back plan
Financial data
10/06/2016
02:00
Weekly report treasury shares buy-back
Products
07/06/2016
02:00
DiaSorin launches the new Helicobacter pylori IgG CLIA test
Financial data
03/06/2016
02:00
Weekly report treasury shares buy-back
Financial data
30/05/2016
02:00
Notice filing By-Laws and publication operating procedures for loyalty shares
Financial data
27/05/2016
02:00
Weekly report treasury shares buy-back
Financial data
20/05/2016
02:00
Weekly report treasury shares buy-back
Acquisition / Partnership
13/05/2016
02:00
Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business
Financial data
12/05/2016
02:00
Start up treasury shares buy-back plan
Financial data
09/05/2016
02:00
The Board of Directors approves the results for Q1'16
Financial data
28/04/2016
02:00
Shareholders' Meeting FY 2015
Acquisition / Partnership
30/03/2016
02:00
DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business
Financial data
09/03/2016
01:00
The Board of Directors approves the results for FY'15

2015

Financial data
11/11/2015
01:00
The Board of Directors approves the results for Q3'15
Products
09/09/2015
02:00
DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias
Financial data
30/07/2015
02:00
H1'15 Results
Acquisition / Partnership
20/07/2015
02:00
DiaSorin and Beckman Coulter sign a distribution agreement for China
Products
28/05/2015
02:00
DiaSorin launches the test for Campylobacter
Other
12/05/2015
02:00
DiaSorin presents the 2015-2017 industrial plan
Financial data
12/05/2015
02:00
The Board of Directors approves the results for Q1'15
Products
29/04/2015
02:00
DiaSorin - launches the test for Brahms-Sepsis
23/04/2015
02:00
DiaSorin supports the Pinocchio Project
Financial data
22/04/2015
02:00
The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day
Financial data
22/04/2015
02:00
Shareholders' meeting approves FY Results 2014
Products
14/04/2015
02:00
DiaSorin launches the tests for Bordetella pertussis
Financial data
10/04/2015
02:00
Investor Day-save the date
24/03/2015
01:00
DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation
Financial data
03/03/2015
01:00
The Board of Directors approves the results for FY'14
24/02/2015
01:00
DiaSorin supports Emergency in Sudan
13/02/2015
01:00
DiaSorin teams with FISIP for Progetto talenti
Products
14/01/2015
01:00
DiaSorin launches the test for Calprotectin

2014

Products
16/12/2014
01:00
FDA approves 1,25 Vitamin D in the US market
Products
09/12/2014
01:00
DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL
Financial data
14/11/2014
01:00
The Board of Directors approves the results for Q3'14
Products
07/10/2014
02:00
DiaSorin launches the test for HIV HT on LIAISON
Products
18/09/2014
02:00
DiaSorin launches the stool test for Adenovirus on LIAISON
Financial data
01/08/2014
02:00
The Board of Directors approves the results for H1'14
Financial data
22/07/2014
02:00
DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME
Products
30/06/2014
02:00
DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM
Products
03/06/2014
02:00
DiaSorin launches the test for Vitamin D 1,25 on LIAISON
Financial data
09/05/2014
02:00
The Board of Directors approves the results for Q1'14
Financial data
23/04/2014
02:00
Shareholders' meeting approves FY Results 2013
Financial data
06/03/2014
01:00
The Board of Directors approves the results for FY'13
Products
18/02/2014
01:00
DiaSorin launches the new test for PTH on LIAISON
Products
11/02/2014
01:00
DiaSorin launches the test for Rotavirus on stool sample
Acquisition / Partnership
28/01/2014
01:00
DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018
Products
24/01/2014
01:00
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China
Products
09/01/2014
01:00
DiaSorin launches the test for Cytomegalovirus on LIAISON IAM

2013

Financial data
08/11/2013
01:00
The Board of Directors approves the Q3'13 Results
Acquisition / Partnership
29/10/2013
01:00
DiaSorin signes a 5-year agreement with Roche
Products
25/10/2013
02:00
DiaSorin launches the EHEC Toxins test on stool samples
Products
10/10/2013
02:00
DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas)
Products
24/09/2013
02:00
DiaSorin launches the hCG test on its LIAISON XL in the US
Financial data
01/08/2013
02:00
The Board of Directors approves the results for the H1 '13
Products
24/07/2013
02:00
DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM
Products
11/07/2013
02:00
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil
Products
28/06/2013
02:00
DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON
Products
20/06/2013
02:00
DiaSorin launches the new test for Parvovirus on LIAISON IAM
Financial data
10/05/2013
02:00
The Board of Directors approves the results for Q1'13
Financial data
02/05/2013
02:00
Compensation Commitee-Errata corrige
Financial data
22/04/2013
02:00
Shareholders' meeting approves FY Results 2012
Products
17/04/2013
02:00
FDA approves the Aldosterone assay
Acquisition / Partnership
02/04/2013
02:00
DiaSorin signs an agreement with Seegene
Financial data
08/03/2013
01:00
The BoD approves FY 2012 results
Financial data
07/03/2013
01:00
Notice availability By-Laws
Financial data
07/03/2013
01:00
Notification of changes in share capital
Financial data
07/02/2013
01:00
Notice availability By-Laws
Financial data
07/02/2013
01:00
Notification of changes in share capital
Products
07/02/2013
01:00
Clostridium difficile on LIAISON (available outside the US and Canada only)
Financial data
30/01/2013
01:00
The Board of Directors approves the results for the FY '12
Products
29/01/2013
01:00
Aldosterone on LIAISON (available outside the US and Canada only)

2012

Financial data
20/12/2012
01:00
Shareholders' meeting
Financial data
07/11/2012
01:00
The BoD approves Q3'12 results
Financial data
03/08/2012
02:00
The BoD approves H1'12 results
Acquisition / Partnership
30/07/2012
02:00
DiaSorin in India: JV with Trivitron Healthcare
Financial data
27/06/2012
02:00
Notification of changes in share capital
Financial data
11/05/2012
02:00
The BoD approves Q1'12 results
Acquisition / Partnership
04/05/2012
02:00
NorDiag acquisition
Financial data
23/04/2012
02:00
2011 statutory financial statement approval
Products
10/04/2012
02:00
Measles and Mumps IgM on LIAISON (available outside the US and Canada only)
Products
02/04/2012
02:00
Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only)
Financial data
30/03/2012
02:00
Financial calendar update
Financial data
22/03/2012
01:00
Stock options to employees
Acquisition / Partnership
12/03/2012
01:00
Agreement with Sonic Healthcare on Vitamin D
Financial data
09/03/2012
01:00
The BoD approves FY 2011 results
Financial data
07/03/2012
01:00
Notification of changes in share capital
Acquisition / Partnership
17/02/2012
01:00
DiaSorin became a member of the ISBT
Financial data
09/02/2012
01:00
Notice of change in share capital
Products
02/02/2012
01:00
FDA clearance for 25 OH Vitamin D on LIAISON
Financial data
27/01/2012
01:00
2012 Financial calendar update
Financial data
25/01/2012
01:00
Dividend distribution in June
Other
19/01/2012
01:00
Prize for best Italian Company in R&D in the UK
Financial data
13/01/2012
01:00
2012 Financial calendar
Products
12/01/2012
01:00
New anti HBs II (available outside the US and Canada only)

2011

Financial data
23/12/2011
01:00
Financial instruments to employees
Products
19/12/2011
01:00
Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only)
Financial data
19/11/2011
01:00
Buy-back plan
Financial data
18/11/2011
01:00
Financial instruments to employees
Financial data
11/11/2011
01:00
The BoD approves Q3'11 results
Financial data
28/10/2011
02:00
Buy-back plan
Financial data
25/10/2011
02:00
Buy-back plan
Financial data
18/10/2011
02:00
Buy-back plan
Financial data
17/10/2011
02:00
2011-2015 Business Plan: a new business wave
Other
10/10/2011
02:00
New Chief Financial Officer
Acquisition / Partnership
06/10/2011
02:00
Cardinal Health: agreement extended to 2014
Financial data
04/10/2011
02:00
Buy-back plan
Other
01/09/2011
02:00
Resignation of Chief Financial Officer
Financial data
31/08/2011
02:00
2011 Financial calendar update
Financial data
03/08/2011
02:00
The BoD approves H1'11 results
Financial data
11/07/2011
02:00
Voluntarily removal from the STAR segment
Financial data
13/05/2011
02:00
The BoD approves Q1'11 results
Acquisition / Partnership
11/05/2011
02:00
DiaSorin and Labcorp extend strategic business relationship
Acquisition / Partnership
06/05/2011
02:00
Agreement with Precision System Science Co., LTD
Financial data
28/04/2011
02:00
The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution
Financial data
16/03/2011
01:00
Dividend information amendment
Financial data
16/03/2011
01:00
The BoD approves FY'10 results
Financial data
28/02/2011
01:00
2011 Financial calendar update
Financial data
19/02/2011
01:00
Notice of change in share capital
Financial data
18/02/2011
01:00
Buy-back plan
Financial data
17/02/2011
01:00
Financial instruments to employees
Financial data
16/02/2011
01:00
Buy-back plan
Financial data
15/02/2011
01:00
Buy-back plan
Financial data
14/02/2011
01:00
The BoD approves Q4'10 results
Financial data
31/01/2011
01:00
Buy-back plan
Financial data
29/01/2011
01:00
Buy-back plan
Financial data
28/01/2011
01:00
Buy-back plan
Financial data
27/01/2011
01:00
Buy-back plan
Products
26/01/2011
01:00
FDA approves the LIAISON XL
Financial data
25/01/2011
01:00
Buy-back plan
Financial data
24/01/2011
01:00
Buy-back plan
Financial data
21/01/2011
01:00
Buy-back plan
Financial data
20/01/2011
01:00
Buy-back plan
Financial data
19/01/2011
01:00
Buy-back plan
Financial data
18/01/2011
01:00
Buy-back plan
Financial data
17/01/2011
01:00
Buy-back plan
Acquisition / Partnership
17/01/2011
01:00
The Sonic Healthcare Group chooses DiaSorin
Financial data
16/01/2011
01:00
2011 Financial calendar

2010

Financial data
22/12/2010
01:00
2011 Financial calendar
Financial data
20/12/2010
01:00
Dividend may be distributed in June
Products
02/12/2010
01:00
Comment on position Paper on Vitamin D
Financial data
24/11/2010
01:00
Change in share capital
Financial data
18/11/2010
01:00
Financial instruments to employees
Financial data
05/11/2010
01:00
The BoD approves Q3'10 results
Financial data
02/11/2010
01:00
Change in share capital
Financial data
08/10/2010
02:00
2010 Financial calendar update
Financial data
30/09/2010
02:00
Change in share capital
Financial data
24/09/2010
02:00
Financial instruments to employees
Financial data
16/09/2010
02:00
Stock options exercised by key managers
Financial data
02/09/2010
02:00
Financial instruments to employees
Financial data
06/08/2010
02:00
The BoD approves H1'10 results
Acquisition / Partnership
07/07/2010
02:00
Agreement with Meridian Inc.
Financial data
06/07/2010
02:00
2010 Financial calendar update
Financial data
02/07/2010
02:00
Financial instruments to employees
Acquisition / Partnership
01/06/2010
02:00
Acquisition of MUREX product line
Financial data
14/05/2010
02:00
The BoD approves Q1'10 results
Financial data
27/04/2010
02:00
Approval of statutory financial statements
Financial data
20/04/2010
02:00
2010 Financial calendar update
Financial data
14/04/2010
02:00
Postponement of the term for lists of members of the Board of Auditors
Products
09/04/2010
02:00
China approves new prenatal screening product line on LIAISON
Financial data
02/04/2010
02:00
Financial instruments to employees
Financial data
22/03/2010
01:00
The BoD approves FY 2009 results
Acquisition / Partnership
10/03/2010
01:00
Acquisition of MUREX product line
Financial data
01/03/2010
01:00
2010 Financial calendar update
Financial data
12/02/2010
01:00
The BoD approves Q4'09 results
Financial data
18/01/2010
01:00
2010 Financial calendar

2009

Financial data
24/12/2009
01:00
Financial instruments to employees
Financial data
30/10/2009
01:00
The BoD approves Q3'09 results
Other
12/10/2009
02:00
Strengthening of group's R&D team
Financial data
08/10/2009
02:00
2009 Financial calendar update
Financial data
05/10/2009
02:00
Financial instruments to employees
Financial data
06/08/2009
02:00
The BoD approves H1'09 results
Financial data
08/06/2009
02:00
2009 Financial calendar update
Financial data
18/05/2009
02:00
Financial instruments to employees
Financial data
10/04/2009
02:00
Corporate Governance Report at December 2008.
Financial data
08/04/2009
02:00
2009 Financial calendar update
Financial data
19/03/2009
01:00
The BoD approves FY 2008 results
Financial data
20/02/2009
01:00
Financial instruments to employees
Financial data
13/02/2009
01:00
The BoD approves Q4'08 results
Financial data
28/01/2009
01:00
2009 Financial calendar
Products
08/01/2009
01:00
FDA clearance to five LIAISON products

2008

Financial data
23/12/2008
01:00
Financial instruments to employees
Financial data
21/11/2008
01:00
Financial instruments to employees
Financial data
13/11/2008
01:00
The BoD approves Q3'08 results
Acquisition / Partnership
22/09/2008
02:00
Agreement in Japan with Advanced Life Science Institute
Financial data
08/08/2008
02:00
The BoD approves H1'08 results
Acquisition / Partnership
09/07/2008
02:00
Acquisition of Biotrin
Financial data
16/05/2008
02:00
Financial instruments to employees
Financial data
15/05/2008
02:00
Results for Q1'08
Financial data
24/04/2008
02:00
2007 statutory financial Statements approved
Financial data
21/04/2008
02:00
2008 Financial calendar update
Financial data
19/03/2008
01:00
The BoD approves FY 2007 results
Financial data
14/02/2008
01:00
The BoD approves Q4'07 results
Financial data
29/01/2008
01:00
2008 Financial calendar
Financial data
07/01/2008
01:00
Financial instruments to employees